1.36
price down icon3.55%   -0.05
after-market 시간 외 거래: 1.31 -0.05 -3.68%
loading
전일 마감가:
$1.41
열려 있는:
$1.25
하루 거래량:
986.47K
Relative Volume:
14.76
시가총액:
$2.96M
수익:
-
순이익/손실:
$-9.32M
주가수익비율:
-0.107
EPS:
-12.7107
순현금흐름:
$-7.30M
1주 성능:
-11.11%
1개월 성능:
-4.90%
6개월 성능:
-45.16%
1년 성능:
-78.92%
1일 변동 폭
Value
$1.20
$1.65
1주일 범위
Value
$1.20
$1.65
52주 변동 폭
Value
$1.20
$7.461

Tharimmune Inc Stock (THAR) Company Profile

Name
명칭
Tharimmune Inc
Name
전화
302-743-2995
Name
주소
1200 ROUTE 22 EAST, BRIDGEWATER
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-08-05
Name
최신 SEC 제출 서류
Name
THAR's Discussions on Twitter

THAR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
THAR
Tharimmune Inc
1.36 2.96M 0 -9.32M -7.30M -12.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Tharimmune Inc 주식(THAR)의 최신 뉴스

pulisher
05:22 AM

THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa

05:22 AM
pulisher
03:01 AM

Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel

03:01 AM
pulisher
11:31 AM

Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener

11:31 AM
pulisher
08:38 AM

FDA greenlights Tharimmune’s drug application pathway - Investing.com India

08:38 AM
pulisher
08:07 AM

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Weatherford Democrat

08:07 AM
pulisher
08:00 AM

FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan

08:00 AM
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat

Mar 24, 2025
pulisher
Mar 24, 2025

Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan

Mar 24, 2025
pulisher
Mar 05, 2025

Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online

Mar 05, 2025
pulisher
Mar 04, 2025

Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider

Mar 04, 2025
pulisher
Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 01, 2025

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World

Mar 01, 2025
pulisher
Feb 27, 2025

Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Tharimmune appoints new CFO following resignation - Investing.com

Feb 27, 2025
pulisher
Feb 25, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 24, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com

Feb 24, 2025
pulisher
Feb 23, 2025

Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Feb 22, 2025
pulisher
Feb 19, 2025

Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter

Feb 19, 2025
pulisher
Feb 17, 2025

Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 17, 2025
pulisher
Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Communications

Feb 13, 2025
pulisher
Feb 07, 2025

Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World

Feb 07, 2025
pulisher
Jan 27, 2025

Tharimmune to Present at the Microcap Conference 2025 - Bellingham Herald

Jan 27, 2025
pulisher
Jan 27, 2025

Tharimmune to Present at Microcap Conference 2025, Showcase Growth Strategy - StockTitan

Jan 27, 2025
pulisher
Jan 25, 2025

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - ACCESS Newswire

Jan 25, 2025
pulisher
Dec 21, 2024

tharimmune CEO Randy Milby buys shares worth $9,752 - Investing.com India

Dec 21, 2024
pulisher
Dec 20, 2024

tharimmune CEO Randy Milby buys shares worth $9,752 By Investing.com - Investing.com Canada

Dec 20, 2024
pulisher
Dec 20, 2024

Tharimmune files to sell 1.44 million shares of common stock by selling shareholders - MSN

Dec 20, 2024
pulisher
Dec 16, 2024

Tharimmune, Inc. Appoints Sanam Parikh to Its Board of Directors - Marketscreener.com

Dec 16, 2024
pulisher
Dec 16, 2024

Tharimmune plans Phase 2 trial for itch treatment TH104 - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Tharimmune plans Phase 2 trial for itch treatment TH104 By Investing.com - Investing.com UK

Dec 16, 2024
pulisher
Dec 16, 2024

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Eagle-Tribune

Dec 16, 2024
pulisher
Dec 16, 2024

Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results - StockTitan

Dec 16, 2024
pulisher
Dec 14, 2024

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN

Dec 14, 2024
pulisher
Dec 11, 2024

Tharimmune announces $2.02M private placement; shares up - MSN

Dec 11, 2024
pulisher
Dec 08, 2024

Tharimmune (NASDAQ:THAR) Coverage Initiated at Rodman & Renshaw - Defense World

Dec 08, 2024
pulisher
Dec 07, 2024

Rodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy Recommendation - MSN

Dec 07, 2024
pulisher
Dec 07, 2024

Tharimmune secures $2.02 million in private funding By Investing.com - Investing.com Nigeria

Dec 07, 2024
pulisher
Dec 06, 2024

THARTharimmune, Inc. Latest Stock News & Market Updates - StockTitan

Dec 06, 2024
pulisher
Dec 06, 2024

Tharimmune secures $2.02 million in private funding - Investing.com

Dec 06, 2024

Tharimmune Inc (THAR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):